



# NANOCARRIER VACCINES

*Biopharmaceutics-Based  
Fast Track Development*



*Edited By*  
VIVEK P. CHAVDA  
VASSO APOSTOLOPOULOS

 Scrivener  
Publishing

WILEY



# Nanocarrier Vaccines

**Scrivener Publishing**

100 Cummings Center, Suite 541J  
Beverly, MA 01915-6106

*Publishers at Scrivener*

Martin Scrivener (martin@scrivenerpublishing.com)  
Phillip Carmical (pcarmical@scrivenerpublishing.com)

# Nanocarrier Vaccines

## Biopharmaceutics-Based Fast Track Development

Edited by

**Vivek P. Chavda**

*Department of Pharmaceutics and Pharmaceutical Technology,  
L. M. College of Pharmacy, Ahmedabad, India*

and

**Vasso Apostolopoulos**

*Institute for Health and Sport, Immunology and Translational Research Group,  
Victoria University, Melbourne, Australia*



**WILEY**

This edition first published 2024 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA

© 2024 Scrivener Publishing LLC

For more information about Scrivener publications please visit [www.scrivenerpublishing.com](http://www.scrivenerpublishing.com).

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

#### **Wiley Global Headquarters**

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

#### **Limit of Liability/Disclaimer of Warranty**

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.

#### ***Library of Congress Cataloging-in-Publication Data***

ISBN 978-1-394-17468-3

Cover image: Pixabay.Com

Cover design by Russell Richardson

Set in size of 11pt and Minion Pro by Manila Typesetting Company, Makati, Philippines

Printed in the USA

10 9 8 7 6 5 4 3 2 1

**Dedicated to the 75th year anniversary of the LM College of  
Pharmacy, Ahmedabad Gujarat India.**



**Vivek P. Chavda also wants to dedicate this book to his wife Disha  
and his parents**





# Contents

---

<b>Preface</b>	<b>xxi</b>
<b>Part 1 General</b>	<b>1</b>
<b>1 History of Nanoparticles</b>	<b>3</b>
<i>Keshava L. Jetha, Arya Vyas, Divya Teli, Amit Chaudhari, Riyansi Satasiya, Vishwa Patel, Shailvi Soni, Shail Modi and Vasso Apostolopoulos</i>	
1.1 Introduction	4
1.2 History of Nanoparticles	5
1.3 Modern Development of Nanoparticles	8
1.4 Type of Nanoparticles	10
1.5 Properties of Nanoparticles	13
1.5.1 Size	14
1.5.2 Shape	14
1.5.3 Surface Area	14
1.6 Importance of Nanoparticles	15
1.7 Conclusion and Future Prospect	18
References	19
<b>2 Composition of Nanoparticles</b>	<b>25</b>
<i>Amit Chaudhari, Palak Vadodariya, Arya Vyas, Disha Patel and Divya Teli</i>	
2.1 Introduction	25
2.2 Types of Nanoparticles	27
2.2.1 Polymeric Nanoparticles	27
2.2.1.1 Polymeric Micelles	27
2.2.1.2 Dendrimer	28
2.2.1.3 Nanosphere	28
2.2.1.4 Nanocapsule	29
2.2.1.5 Polymersome	29
2.2.1.6 Nanocomplex	31

2.2.1.7	Nanogel	31
2.2.2	Inorganic Nanoparticle	32
2.2.2.1	Gold Nanoparticle	32
2.2.2.2	Silica Nanoparticle	32
2.2.2.3	Magnetic Nanoparticle	33
2.2.2.4	Quantum Dots	33
2.2.2.5	Nanocarbon	34
2.2.3	Hybrid Nanoparticle	34
2.2.3.1	Cell Membrane Coated Nanoparticle	34
2.2.3.2	Lipid Polymer Nanoparticle	35
2.2.3.3	Organic–Inorganic Nanocomposite	36
2.2.4	Bioinspired Nanoparticle	36
2.2.4.1	Exosomes	36
2.2.4.2	Protein Nanoparticle	37
2.2.4.3	DNA Nanostructure	37
2.2.5	Lipid-Based Nanoparticle	38
2.2.5.1	Liposome	38
2.2.5.2	Lipoplex	39
2.2.5.3	Solid Lipid Nanoparticle	39
2.3	Composition of Nanoparticles	40
2.3.1	Chitosan	40
2.3.2	Albumin	41
2.3.3	Polylactic Acid	42
2.3.4	Poly lactide-co-glycolide (PLGA)	43
2.3.5	Polyacrylate	44
2.4	Synthesis of Nanoparticles	45
2.4.1	Top–Down Approach	46
2.4.1.1	Ball Milling	46
2.4.1.2	Physical Vapor Deposition (PVD)	47
2.4.1.3	Melt Mixing	47
2.4.1.4	Pulse Laser Ablation	47
2.4.2	Bottom-Up Approach	48
2.4.2.1	Chemical Vapor Deposition (CVD)	48
2.4.2.2	Thermal Decomposition Method	48
2.4.2.3	Chemical Methods	49
2.4.2.4	Biological Methods	49
2.5	Nanoparticle Characterization by Various Instrumental Techniques	50
2.5.1	Dynamic Light Scattering (DLS)	50
2.5.2	Zeta Potential	51

2.5.3	Microscopic Techniques to Characterize Nanoparticles	51
2.5.3.1	Scanning Electron Microscopy (SEM)	51
2.5.3.2	Transmission Electron Microscopy (TEM)	51
2.5.4	Spectroscopic Techniques to Characterize Nanoparticles	52
2.5.4.1	Ultraviolet-Visible Spectroscopy (UV-Vis)	52
2.5.4.2	Raman Spectroscopy	52
2.5.4.3	Fourier Transform Infrared Spectroscopy (FTIR)	52
2.5.5	X-Ray Diffraction Method (XRD)	53
2.6	Understanding Nanotoxicity: Potential Risks and Implications	53
2.7	Conclusion	54
	References	54
<b>3</b>	<b>Nanotechnology and Vaccine Development</b>	<b>63</b>
	<i>Keshava L. Jetha, Praful D. Bharadia and Manish P. Patel</i>	
3.1	Introduction	63
3.2	Overview of Vaccine Development	64
3.3	Advantages of Nanoparticles in Vaccine Delivery	66
3.4	Types of Nanoparticles as Vaccine Carriers	67
3.4.1	Liposomes	67
3.4.2	Polymer-Based Nanoparticles	67
3.4.3	Virus-Like Particles (VLPs)	67
3.4.4	Nanogels	67
3.4.5	Inorganic Nanoparticles	67
3.5	Development of Nanoparticle-Based Vaccine	70
3.5.1	Viral Vector-Based Nanoparticle	70
3.5.2	Lipid-Based Nanoparticles	70
3.5.3	DNA-Based Nanoparticles	71
3.5.4	mRNA-Based Nanoparticles	71
3.5.5	Protein-Based Nanoparticles	71
3.6	Adjuvants and their Role in Vaccine Development	72
3.7	Nanoscale Adjuvants	74
3.8	Advantages	75
3.9	Techniques for Nanoscale Adjuvants	76
3.10	Route of Administration for Vaccines	77
3.11	Recent Advances in Nanotechnology-Based Vaccines	79
3.12	The Regulatory Perspective of Nanoparticle-Based Vaccine Development	80

3.13	Future Prospects	81
3.14	Conclusion	84
	References	85
<b>4</b>	<b>Nanoparticle Formulations: A Sustainable Approach to Biodegradable and Non-Biodegradable Products</b>	<b>95</b>
	<i>Amandeep Singh, Shreni Parikh, Nutan Sethi, Sachin Patel, Nrupal Modi and Kaushika Patel</i>	
4.1	Introduction	96
4.2	Types of Nanoparticles	96
4.3	Preparation of Nanoparticles	100
4.4	Factors Affecting Selection of Method	100
4.4.1	Pressure	105
4.4.2	Particle Shape and Size	105
4.4.3	Environment	105
4.4.4	Pore Size	106
4.4.5	Particular Method or Technique	106
4.4.6	Cost of Preparation	106
4.4.7	Proximity	106
4.4.8	Time	106
4.4.9	Other Variables	106
4.5	Polymers Used in NP Formulation	107
4.6	Nanoparticle Formulations Based on Biodegradable Polymers	107
4.7	Nanoparticle Formulations Based on Non-Biodegradable Polymers	115
4.8	Nanoparticle Formulations Based on Natural Polymers	118
4.9	Challenges in NPs from Laboratory to Industrial Scale-Up	121
4.10	Nanoparticle-Based Approved & Marketed Formulations	122
4.11	Future Aspects & Conclusion	122
	References	135
<b>5</b>	<b>Nanoparticle Properties: Size, Shape, Charge, Inertness, Efficacy, Morphology</b>	<b>153</b>
	<i>Kajal P. Baviskar, Brijesh M. Shah, Anjali P. Bedse, Shilpa S. Raut, Suchita P. Dhamane and Dhara J. Dave</i>	
5.1	Introduction	154
5.2	Applications of Nanoparticle Formulations	155
5.3	Interaction with Cells	157
5.4	Properties of Nanoparticles	159
5.4.1	Classification of Nanoparticle Properties	159

5.4.1.1	Physicochemical Properties	159
5.4.1.2	Optical Properties	160
5.4.1.3	Magnetic Properties	160
5.4.1.4	Catalytic Properties	161
5.4.1.5	Mechanical Properties	161
5.4.2	Different Properties	162
5.4.2.1	Size	162
5.4.2.2	Shape	163
5.4.2.3	Charge	168
5.4.2.4	Inertness	170
5.4.2.5	Efficacy	171
5.4.2.6	Morphology	173
5.5	Role of Physicochemical Properties in Nanoparticle Toxicity	174
5.6	Conclusion	177
	References	178

## **Part 2 Nanoparticles to Deliver Antigen 193**

### **6 Viral Vector–Based Nanoparticles 195**

*Suneetha Vuppu, Vivek P. Chavda, Toshika Mishra,  
Oishani Sengupta, Anand Sairam, Paridhi Soni,  
Mohit Joshi, Bhumi Bhalodiya and Raj V.*

6.1	Introduction	196
6.2	Characteristics of Viral Vector–Based Nanoparticles	197
6.3	Applications	199
6.3.1	Viral Nanoparticles for Drug Delivery	201
6.3.1.1	Antimicrobial Therapies	202
6.3.1.2	Cardiovascular Therapies	203
6.3.2	Viral Nanoparticles for Imaging	203
6.3.2.1	Nanoparticles are Used in PET/SPECT Scans	211
6.3.2.2	Nanoparticles Used in Ultrasonic Tests	215
6.3.2.3	Nanoparticles Utilized in CT Scans	215
6.3.2.4	Nanoparticles Employed in MRI Biomedical Applications	215
6.3.2.5	Illustrations of Nanoparticles Utilized in Fluorescence-Based Biological Applications	215
6.3.3	Viral Nanoparticles for Immunotherapy	215
6.3.4	Viral Nanoparticles for Theranostic Applications	216
6.4	Novel Advancements in Applications of Viral Nanoparticles	225
6.5	Limitations and Prospects of Viral Vector–Based Nanoparticle Approach	233

6.6	Conclusion	234
	Acknowledgment	235
	References	235
<b>7</b>	<b>Lipid-Based Nanoparticles</b>	<b>241</b>
	<i>Sunny Shah, Hardik Madhu, Moinuddin Soniwala, Dhaval Mori, Amit Vyas, Advaita Chauhan and Bhupendra Prajapati</i>	
7.1	Introduction	242
7.2	Types of Lipid-Based Nanoparticles	243
	7.2.1 Solid Lipid Nanoparticles (SLNs)	243
	7.2.2 Nanostructured Lipid Carriers (NLCs)	244
7.3	Synthesis of Lipid-Based Nanoparticles	245
	7.3.1 Introduction to Lipids	245
	7.3.2 Methods for Formulating Lipid Nanoparticles	245
	7.3.2.1 High-Pressure Homogenization	246
	7.3.2.2 Solvent Emulsification–Evaporation	246
	7.3.2.3 Microemulsion-Based Method	247
	7.3.2.4 Hot-Melt Homogenization	248
	7.3.2.5 Spray Drying	249
	7.3.2.6 Solvent Injection Method	249
	7.3.2.7 Microfluidics	250
7.4	Characterization of Lipid Nanoparticles	251
	7.4.1 Size and Shape	251
	7.4.2 Surface Charge	252
	7.4.2.1 Analytical Techniques for Surface Charge Characterization	253
	7.4.2.2 Zeta Potential Measurement	253
	7.4.2.3 Electrophoresis	253
	7.4.2.4 Isoelectric Focusing	253
	7.4.3 Encapsulation Efficiency	254
	7.4.3.1 Factors Affecting Encapsulation Efficiency	254
	7.4.3.2 Analytical Techniques for Encapsulation Efficiency Characterization	254
	7.4.4 Stability	255
	7.4.4.1 Factors Affecting Stability	256
	7.4.4.2 Analytical Techniques for Stability Characterization	256
7.5	Applications of Lipid-Based Nanoparticles in Vaccines	257
	7.5.1 Enhancement of Immune Response	257
	7.5.2 Targeted Delivery	258

7.5.2.1	Cancer Immunotherapy	259
7.5.2.2	mRNA-Based Vaccines	259
7.5.2.3	Gene Therapy	259
7.5.3	Adjuvant Effects	259
7.5.3.1	mRNA COVID-19 Vaccines	260
7.5.3.2	Human Papillomavirus (HPV) Vaccine	260
7.5.3.3	Influenza Vaccine	260
7.6	Challenges and Future Directions	261
7.6.1	Safety and Toxicity Concerns	261
7.6.1.1	Preclinical Safety Evaluation	261
7.6.1.2	Human Pharmacology Studies	261
7.6.1.3	Postmarketing Surveillance	262
7.6.1.4	Adverse Event Reporting	262
7.6.2	Stability Issues	262
7.6.2.1	Formulation Optimization	263
7.6.2.2	Analytical Method Development	263
7.6.2.3	Accelerated Stability Studies	263
7.6.2.4	Quality by Design (QbD)	263
7.6.3	Scale-Up Production Challenges	264
7.6.3.1	Equipment Design	264
7.6.3.2	Process Optimization	264
7.6.3.3	Regulatory Compliance	264
7.6.4	Opportunities for Future Research	265
7.6.4.1	Novel Antigen and Adjuvant Formulations	266
7.6.4.2	Targeted Delivery	266
7.6.4.3	Manufacturing Process Optimization	266
7.6.4.4	Immunological Mechanisms	266
7.6.4.5	Opportunities for Future Research	266
7.7	Conclusion	267
	References	268
<b>8</b>	<b>Nanoparticle-Based mRNA Vaccines: Are We One Step Closer to Targeted Cancer Therapy?</b>	<b>275</b>
	<i>Lakshmi Vineela Nalla, Siva Nageswararao Gajula and Vivek P. Chavda</i>	
8.1	Introduction	276
8.2	Use of mRNA in Vaccines: Advantages and Challenges	278
8.3	How Do mRNA Vaccines Work?	279
8.4	Nanocarriers for mRNA Delivery	281
8.4.1	Liposomes and RNA Lipoplexes	282

8.4.2	Lipid Nanoparticles	283
8.4.3	Polymer-Based Nanoparticles	283
8.4.4	Hybrid Nanoparticles	284
8.5	Nanoparticle-Based mRNA Vaccines in Cancer Therapy	285
8.5.1	Breast Cancer	285
8.5.2	Colorectal Cancer	287
8.5.3	Lung Cancer	288
8.5.4	Glioma Tumor	289
8.5.5	Other Tumors	291
8.6	Clinical Trials	291
8.6.1	Considerations for Clinical Translation	293
8.7	Conclusion	295
	References	297
<b>9</b>	<b>Protein Delivery by Nanoparticles</b>	<b>305</b>
	<i>Harshita Gauraha, Ankita Bhadoriya, Rupesh K. Gautam and Dinesh Kumar Mishra</i>	
9.1	Introduction	305
9.2	Major Challenges in Protein Delivery	307
9.3	Nanotechnology	308
9.4	Nanoparticles	310
9.4.1	Nanocarriers	311
9.4.2	Protein Nanocarrier	312
9.4.3	Protein and Its Type Used to Produce Protein Nanoparticles	312
9.4.3.1	Silk Protein Fibroin	313
9.4.3.2	Human Serum Albumin	314
9.4.3.3	Gliadin	314
9.4.3.4	Gelatin	315
9.4.3.5	Legumin	316
9.4.3.6	30Kc19 Protein Obtained from Silkworm Hemolymph	316
9.4.3.7	Ferritin	317
9.5	Methods of Preparation	317
9.5.1	Chemical Methods	317
9.5.1.1	Emulsion/Solvent Extraction	317
9.5.2	Physical Method	320
9.5.2.1	Nano Spray Drying	320
9.5.2.2	Electrospraying Technique	321
9.5.2.3	Self-Assembly	321



9.5.2.4	Desolvation	322
9.6	Nanoformulations Available for Protein and Peptide Delivery	322
9.6.1	Dendrimers	323
9.6.2	Liposomes	324
9.6.3	Solid Lipid Nanoparticles	324
9.6.4	Polymeric Nanoparticles	324
9.6.5	Polymeric Micelles	325
9.7	Clinical Trials and Market-Approved Nanoparticles	325
9.7.1	Nanomedicine and Proteins in the Field of Treatment and Diagnosis	327
9.8	Characterization of Protein Nanoparticles	329
9.8.1	Particle Size and Polydispersity	330
9.8.2	Particle Morphology	330
9.8.3	Particle Structure/Surface Charge	330
9.8.4	Drug Loading and Release	331
9.9	Applications of Protein Nanoparticles	331
9.9.1	Routes	331
9.9.1.1	Oral Route	331
9.9.1.2	Nasal and Pulmonary Route	333
9.9.1.3	Blood–Brain Barrier Route	333
9.9.1.4	Transdermal Delivery	333
9.9.2	Non-Viral Gene Therapy	334
9.9.3	Immunological Adjuvant	334
9.9.4	Antibiotics	334
9.9.5	Diseases	335
9.9.5.1	Tuberculosis (TB)	335
9.9.5.2	Cancer Therapy	335
9.9.5.3	Leishmaniasis	336
9.9.5.4	Rheumatoid Arthritis	336
9.10	Conclusion	336
9.11	Future Developments	337
	References	337

## **Part 3 Route of Administration** **345**

### **10 Oral Vaccine Delivery: Current Status** **347**

*Pankti C. Balar, Vidhi A. Modh, Sanjay P. Chauhan, Hetvi K. Solanki, Rajeshkumar K. Patel, Dasharath M. Patel and Maharshi B. Padya*

#### 10.1 Introduction 348

10.2	Need for Oral Vaccines	349
10.3	Nanoparticles as an Oral Vaccine Delivery System	350
10.3.1	Lipid Nanoparticles	353
10.3.2	Polymeric Nanoparticles	353
10.3.3	Vesicular Delivery	354
10.4	Advantages of Oral Nanovaccines	355
10.5	Drawbacks and Disadvantages of Oral Nanovaccines	355
10.6	Barriers in Oral Vaccines Delivery	356
10.6.1	Physiological Barrier	356
10.6.2	Immunological Barrier	357
10.7	Currently Licensed Oral Vaccines	357
10.8	Descriptions of Licensed Oral Vaccines	360
10.8.1	Oral Polio Vaccine	360
10.8.2	Live Oral Typhoid Vaccine	360
10.8.3	Cholera Vaccine	360
10.8.4	Rotavirus Vaccine	361
10.8.5	Oral Adenovirus Vaccine	361
10.9	Conclusion and Future Prospect	361
	References	362
<b>11</b>	<b>Nanovaccines for Mucosal Immunity</b>	<b>367</b>
	<i><b>Shashi Kiran Misra, Anupria Kapoor and Kamla Pathak</b></i>	
11.1	Introduction	368
11.2	Mucosal Immunity	372
11.3	Nanovaccine Formulations	375
11.3.1	Polymer-Based Nanovaccines	379
11.3.1.1	Polylactide-co-Glycolide (PLGA)-Based Mucosal Nanovaccines	379
11.3.1.2	Chitosan-Based Mucosal Nanovaccines	380
11.3.1.3	Alginate-Based Mucosal Vaccines	382
11.3.1.4	Beta Glucan-Based Mucosal Vaccines	383
11.3.1.5	Poly-( $\epsilon$ -Caprolactone)/Chitosan-Based Mucosal Vaccines	383
11.3.2	Carbon Nanotube-Based Mucosal Vaccines	384
11.3.3	Inorganic Nanoparticle-Based Mucosal Vaccines	387
11.3.3.1	Silica-Based Nanoparticles	387
11.3.3.2	Gold Nanoparticles (AuNPs)	390
11.3.4	Virus-Like Particles (VLP)-Based Mucosal Vaccines	390
11.4	Future Perspectives	393

11.5	Conclusion	396
	References	396
<b>12</b>	<b>Nanovaccine via Intramuscular, Subcutaneous, and Intradermal Routes</b>	<b>405</b>
	<i>Dixa A. Vaghela, Maharshi Bhailalbhai Pandya, Pooja M. Parmar, Sanjay P. Chauhan, Akta Vaishnav, Rajeshkumar K. Patel, Dasharath M. Patel, Vidhi Ankit Modh and Mihir K. Raval</i>	
12.1	Introduction	406
	12.1.1 What is a Nanovaccine?	407
12.2	History of Nanovaccination	408
12.3	Introduction to the Route of Administration	409
	12.3.1 Intramuscular	409
	12.3.2 Subcutaneous	411
	12.3.3 Intradermal	413
12.4	Comparable Adaptive Immune Response After IM, SC, and ID Routes	415
12.5	Marketed Formulation	416
12.6	Challenges of Vaccine Delivery	417
12.7	Conclusion	418
	Acknowledgment	418
	References	418
<b>Part 4</b>	<b>Application and Advances</b>	<b>423</b>
<b>13</b>	<b>Nanovaccines for Veterinary Applications</b>	<b>425</b>
	<i>Suneetha Vuppu, Vivek P. Chavda, Toshika Mishra, Swati Punetha, Nikita Sharma, Sathvika Kamaraj and Raj V.</i>	
13.1	Introduction	426
	13.1.1 Diverse Types of Nanovaccines in the Veterinary Field	427
	13.1.1.1 Polymeric Nanoparticles	427
	13.1.1.2 Liposomes	428
	13.1.1.3 Fullerenes and Bucky Tubes	428
	13.1.1.4 Microbivores and Respirocytes	428
	13.1.1.5 Nanoshells	428
	13.1.1.6 Quantum Dots	428
	13.1.1.7 Solid Lipid Nanoparticles	428
	13.1.1.8 Magnetic Iron Oxide Nanoparticles	429
	13.1.1.9 Dendrimers	429

13.1.1.10	Nanoemulsions	429
13.1.1.11	Nanobubbles	429
13.1.1.12	Aluminosilicate Nanoparticles	429
13.1.1.13	Polymeric Micelles	429
13.1.1.14	Polymer-Coated Nanocrystals	430
13.1.1.15	Polymeric Nanospheres	430
13.1.1.16	Metallic Nanoparticles	430
13.2	Nanovaccines and Immune Response	431
13.3	Vaccine Production	433
13.4	Veterinary Applications of Nanovaccines	435
13.4.1	Disease Prevention in Cattle	435
13.4.1.1	Viral Diseases	436
13.4.1.2	Bacterial Diseases	438
13.5	Comparative Analysis of Animal Vaccines, Nanovaccines, and Edible Vaccines	439
13.6	Regulation of Vaccine Production Process	441
13.7	New Approaches	450
13.8	Applications of Different Polymer-Based Nanoparticles	451
13.9	Future Prospects	453
13.10	Conclusion	454
	Acknowledgments	455
	References	455
<b>14</b>	<b>Regulatory Pathways for Nanocarrier Vaccine</b>	<b>465</b>
	<i>Niva Rani Gogoi, Rajashri Bezbaruah, Vishwa Patel, Riyansi Satasia, Bedanta Bhattacharjee and Bhaskar Mazumder</i>	
14.1	Introduction	466
14.2	The Need for a Regulatory Framework	467
14.3	Regulatory Requirements for the Manufacturing of NVs	469
14.3.1	Upstream Manufacturing Process	469
14.3.2	Downstream Manufacturing Process	469
14.4	Clinically Approved Nanocarrier Vaccines	470
14.5	Regulatory Challenges	474
14.5.1	Existing Regulatory Guidelines are not Adequate for the Regulation of Nanocarrier Vaccines	475
14.5.2	Lack of an Appropriate Risk Governance Organization	475
14.5.3	No Act is Nanovaccine-Specific Framed	476
14.5.4	Lack of Proper Regulatory Framework for Patentability	476
14.6	Global Strategies for Clinical Approval	476

14.6.1	The United States of America	476
14.6.2	The European Union	477
14.6.3	The United Kingdom	478
14.6.4	Canada	478
14.6.5	Japan	478
14.6.6	Other Countries	479
14.7	Conclusion and Future Prospects	479
	References	479
<b>Index</b>		<b>487</b>



## Preface

---

In nanomedicine and nano-delivery systems, materials in the nanoscale range are used as diagnostic instruments or to administer therapeutic compounds to particular targeted regions in a controlled manner. By delivering precise medications to specified locations and targets, nanotechnology provides several advantages in treating chronic human illnesses. The use of nanomedicine (including chemotherapeutic medicines, biological agents, immunotherapeutic agents, etc.) in the treatment of various diseases has recently seen many notable applications. This book aims to be a single source material for understanding all the current and novel advancement in the field of nanotechnology.

Chapter 1 discusses the history and constantly evolving field of nanoparticles. Chapter 2 describes the overall composition of a nanoparticle. The next chapters explain the formulation strategy and the influencing factors in therapeutic approaches, such as vaccine development (Chapter 3), biodegradable and non-biodegradable formulation, and properties such as size, shape, charge, inertness, efficacy, morphology, and more (Chapters 4 and 5). Different nanoparticles, such as lipid-based, viral vector-based, and metal, uphold very significant properties individually, which suggests their applicability in various management tactics, as described in Chapters 6 and 7.

Chapters 8 and 9 examine how genetic information carrying entities are becoming the norm for evacuating tedious diseases. Furthermore, Chapters 10, 11, and 12 gather an exhaustive amount of information on routes of administration for the same, such as the oral route, mucosal immunity, intramuscular, subcutaneous, and intradermal. This treatment has had an astonishing effectiveness in veterinary disease management, as described in Chapter 13. Finally, Chapter 14 explores the legal regulatory for nanotechnology-based approaches.

We hope this book will help to bolster your knowledge on this vastly changing and expanding subject. Our thanks go to the prestigious Wiley and Scrivener Publishing for their continuous kind support and guidance.

**Editors**

Vivek P. Chavda and Vasso Apostolopoulos



**Part 1**  
**GENERAL**



# History of Nanoparticles

Keshava L. Jetha<sup>1,2</sup>, Arya Vyas<sup>1</sup>, Divya Teli<sup>3</sup>, Amit Chaudhari<sup>3</sup>,  
Riyansi Satasiya<sup>3</sup>, Vishwa Patel<sup>3</sup>, Shailvi Soni<sup>4</sup>,  
Shail Modi<sup>4</sup> and Vasso Apostolopoulos<sup>5\*</sup>

<sup>1</sup>*Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat, India*

<sup>2</sup>*Gujarat Technological University, Chandkheda, Ahmedabad, Gujarat, India*

<sup>3</sup>*Department of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad, Gujarat, India*

<sup>4</sup>*Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, MA, USA*

<sup>5</sup>*Institute for Health and Sport, Victoria University, Immunology and Translational Research Group, Melbourne, VIC, Australia*

---

## **Abstract**

Nanoparticles (NPs) have become a widely researched area in modern medicine due to their unique properties and potential applications. This article provides an overview of the field of NPs in healthcare, starting with a brief introduction to NPs and their history. The article then delves into modern developments in the field of NPs, including their production and various applications. It also covers the different types of NPs that have been studied, along with their properties and advantages. Furthermore, the article discusses the importance of NPs in various healthcare areas, such as drug delivery, medical imaging, and diagnostics. Finally, the article concludes with a summary of the current state of the field and the future prospects for NPs in healthcare. Understanding the properties and potential applications of NPs can contribute to the development of innovative medical therapies and advance the field of healthcare.

**Keywords:** Nanoparticles, history, medical imaging, diagnosis, future prospects

---

\*Corresponding author: [vasso.apostolopoulos@vu.edu.au](mailto:vasso.apostolopoulos@vu.edu.au)

## 1.1 Introduction

Nanoparticles (NPs) have emerged as a potential research area in nanotechnology that frequently appears in materials science, biomedical engineering, and nanomedicine sectors. A NP is the fundamental unit in the fabrication of a nanostructure with one or more nanometric dimensions ranging in size that may differ from the bulk material. The word “nano” represents a nanometer (nm,  $10^{-9}$  m), an International System of Unit for length. In principle, NPs are materials with lengths ranging from 1 to 100 nm. There are numerous examples from ancient times where nanostructures or NPs have been used for various purposes. The varieties of glorious colors of glass windows of medieval cathedrals are an ancient witness to the utilization of metal oxide NPs [1]. NPs evolved in different eras and from different regions such as hand stencils of Sulawesi cave in Indonesia and hair dyes with lead sulfide NPs in Egypt. Mesopotamia and Egypt produced glassware using inorganic NPs in the fourteenth century BC [2].

The different types of NP classifications, functionalization techniques, various types of synthesis approaches, and growth-related mechanisms are evolved. NPs may be classified into various groups related to dimensionality space; morphology major groups are organic polymeric NPs, inorganic NPs, ceramic NPs, and bionanoparticles [3]. NPs can be synthesized either from a simple material or using a range of multiple composite objects. The synthesis methods of NM are generally classified into “top-down” and “bottom-up” approaches. In the top-down approach, a solid material is broken into smaller particles by external forces, while in the bottom-up approach, nanostructures are synthesized through the buildup of molecules or atoms. These synthetic approaches can be further differentiated by chemical, physical, and biological processes that, through improvement over time, also emerged as including mechanochemical and physiochemical processes. In the current scenario, tremendous metallic nanomaterials are being synthesized in bulk using titanium, copper, zinc, magnesium, alginate, aluminum oxide, silica, gold, and silver.

NPs are widely used to improve the pharmaceutical properties of medicines including penetration, plasma distribution, half-life, and target site accumulation. Size, shape, charge, and elasticity are physical properties of NPs and play a role to provide desired pharmacokinetic properties for implementation in drug delivery systems. Mechanical properties of NPs include elasticity; these overcome biological barriers from the site of application to the site of solid tumor and provide superior cancer drug delivery [4]. NPs have diverted physical and chemical characteristics from bulk


material and show a wide range of applications in a multitude of fields, such as medical treatments; use in various industry departments; the manufacture of oxide fuel; and solar batteries for energy storage, cosmetics, and clothes. Nanotechnology can also enhance the properties of construction materials, where recycling concrete with NPs support sustainability [5]. Nanotechnology-based products used for the control of disease in the healthcare system are referred to as “nanomedicine.” In recent years, nano-sized compounds such as liposomes, polymers, and virus-sized NPs become attractive development as targeted delivery vehicles for viral antigens. NPs provide similar size distribution as the viruses and therefore NPs loaded with viral antigens can enter the virus-targeted cells. In recent years, the utilization of NPs has also expanded toward vaccine delivery with high bioavailability, elevated immunogenicity, and controlled release profiles [6].

## 1.2 History of Nanoparticles

Although NPs have been studied for centuries, the term was not coined until the late 1970s. In 1959, Nobel Prize-winning American physicist Richard Feynman proposed the concept of nanotechnology. “There’s Plenty of Space at the Bottom” was the title of a lecture Feynman gave at the California Institute of Technology at the American Physical Society’s annual meeting (Caltech). The question “Why can’t we write the full 24 volumes of the Encyclopaedia Britannica on the head of a pin?” was posed by Feynman in this lecture, and he also sketched out a vision of utilizing machines to build smaller machines all the way down to the molecular level [7]. Refer to Figure 1.1.

Feynman’s position as the father of modern nanotechnology was finally cemented by the validation of the ground-breaking idea he offered. Approximately 15 years later, in 1974, Japanese scientist Norio Taniguchi used the word “nanotechnology” for the first time. He defined nanotechnology as the manipulation of materials at the atomic or molecular scale by procedures like separation, consolidation, and deformation [8].

NPs have been utilized for centuries before Feynman put forward the concept of nanotechnology. More than 4,500 years ago, humans used natural asbestos nanofibers to reinforce ceramic matrix materials. More than 4,000 years ago, the ancient Egyptians used nanomaterials (NM) as well. They produced PbS NPs with a diameter of about 5 nm for use in hair dye. When Egyptians and Mesopotamians began employing metals to make



**Figure 1.1** The evaluation of NPs on the basis of broad terms including chemistry, biology, and physics. Adopted under CC BY 4 from [8].

glass in the 14th and 13th centuries BC, it may be said that the period of metallic NPs began. Since then, metallic NPs have been synthesized via chemical processes. One of the most intriguing examples of nanotechnology in the ancient world was presented by the Romans in the fourth century AD, who employed NPs and structures. Yet, the most well-known use of ancient metallic NPs is on a piece of Roman glass. The Lycurgus cups are dichroic glass cups from the fourth century AD that show different colors depending on the direction of the light: red when it comes from behind and green when it comes from the front. To understand the dichroism phenomena, scientists examined the cup in 1990 using a transmission electron microscope. The presence of NPs with a diameter of 50–100 nm is what causes the dichroism (two colors) that has been seen. These NPs were identified by X-ray analysis as silver–gold (Ag–Au) alloy with an Ag: Au ratio of